Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Glaucoma Drop Aids Part 2

NCT: NCT06806332 · NOT_YET_RECRUITING

NCT IDNCT06806332
StatusNOT_YET_RECRUITING
Start Date2026-07
Completion2027-06

Brief Summary

Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.

Frequently Asked Questions

What is Glaucoma Drop Aids Part 2?

Glaucoma Drop Aids Part 2 is a clinical trial registered under NCT06806332. Current status: NOT_YET_RECRUITING.

What is the status of NCT06806332?

The current status of NCT06806332 (Glaucoma Drop Aids Part 2) is: NOT_YET_RECRUITING.

When did Glaucoma Drop Aids Part 2 start?

Glaucoma Drop Aids Part 2 started on 2026-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.